Similar articles

• [Prostaglandin treatment of ductus-dependent congenital heart defects].

  Olsson B, Björkhem G, Lundström NR. Olsson B, et al. Lakartidningen. 1984 Oct 3;81(40):3619-22. Lakartidningen. 1984. PMID: 6541738 Swedish. No abstract available.
• [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].

  Fujii S, Nagai I, Yonei A, Sari A, Baba K. Fujii S, et al. Masui. 1984 May;33(5):545-9. Masui. 1984. PMID: 6540818 Japanese. No abstract available.
• [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].

  Kertész E, Hencz P, Tekulics P, Beviz J, Száva J, Matkó I, Kovács G. Kertész E, et al. Orv Hetil. 1980 May 18;121(20):1197-9. Orv Hetil. 1980. PMID: 7413203 Hungarian. No abstract available.
• The ductus arteriosus: why and how to manipulate its patency.

  Drummond WH, Bucciarelli RL, Gessner IH. Drummond WH, et al. J Fla Med Assoc. 1983 Sep;70(9):788-93. J Fla Med Assoc. 1983. PMID: 6355376 Review. No abstract available.
• Use of prostaglandins in cardiopulmonary diseases of the newborn.

  Olley PM, Coceani F. Olley PM, et al. Semin Perinatol. 1980 Apr;4(2):135-41. Semin Perinatol. 1980. PMID: 6990504 Review. No abstract available.